JMP Securities Reiterates Market Perform Rating on Incyte (INCY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incyte (INCY) Announces Positive Topline Results from Pivotal Study of Tafasitamab in R/R Follicular Lymphoma
August 15, 2024 4:30 PM EDTIncyte (Nasdaq: INCY) today announces positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide and rituximab compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL).
The trial met its primary endpoint of progression free survival (PFS) by investigator assessment in FL. It also met key secondary endpoints of PFS in the overall population by investigator assessment as well as the positron-emission tomography-complete... More
Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi
August 15, 2024 9:27 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $34.00 (from $30.00) while maintaining a Buy rating.
The analyst comments "Today, the FDA approved INCY/SNDXs Niktimvo in 3L+ cGvHD at the recommended dosage of... More
BMO Capital Reiterates Underperform Rating on Incyte (INCY)
August 15, 2024 8:57 AM EDTBMO Capital analyst Evan Seigerman reiterated an Underperform rating and $48.00 price target on Incyte (NASDAQ: INCY).
The analyst commented, "Today's FDA decision to approve axatilimab, now Niktimvo, in 3L+ cGVHD comes as expected for most investors, albeit slightly ahead of the 8/28... More
Incyte (INCY) PT Raised to $67 at RBC Capital
August 15, 2024 6:14 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $67.00 (from $66.00) while maintaining a Sector Perform rating.
The analyst comments "Although axatilimabs approval came earlier than expected, we believe it was largely already baked into valuation, launch is delayed... More
